comparemela.com

Latest Breaking News On - Virtual webcast event - Page 1 : comparemela.com

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and.

United statesTimothya yapMaria koehlerLloydm segalRepare therapeutics incHead of clinical developmentExchange commissionInternational conference on molecularCompany quarterly report on formUniversity of texas md anderson cancer centerCompany nasdaqCompany virtual webcast eventDepartment of investigational cancer therapies phaseTherapeutics discovery divisionCompany annual report on formRepare therapeutics

Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials

Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed. | June 7, 2023

Maria koehlerLloydm segalCompany nasdaqRepare therapeutics incPrincess margaret cancer centerCompany virtual webcast eventCanadian cancer trials groupRepare therapeuticsChief medical officerChief executive officerInitial findingsVirtual webcast eventRepare therapeutics inc stock exchangePress releaseNcluding rptx us7602731025

Repare Therapeutics : Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics SNIPRx platform for molecular selection of tumors for therapy with RP-3500 - Form 8-K

Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics SNIPRx platform for molecular selection of tumors for therapy with RP-3500 . | October 8, 2021

United statesUnited kingdomDavid rosenTimothy yapMaria koehlerKimberly minarovichLloydm segalSteve forteDivision of cancer medicineCompany nasdaqCompany virtual webcast eventMd anderson cancer centerRepare therapeutics incExchange commissionVirtual international conference on molecularInstitute for applied cancer science

vimarsana © 2020. All Rights Reserved.